ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Genprex Inc

Genprex Inc (GNPX)

2.17
-0.25
(-10.33%)
Closed June 15 4:00PM
2.16
-0.01
(-0.46%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
2.17
Bid
2.22
Ask
4.50
Volume
81,619
2.12 Day's Range 2.47
2.09 52 Week Range 42.00
Market Cap
Previous Close
2.42
Open
2.47
Last Trade
1
@
2.22
Last Trade Time
Financial Volume
$ 183,478
VWAP
2.248
Average Volume (3m)
110,349
Shares Outstanding
1,485,871
Dividend Yield
-
PE Ratio
-0.10
Earnings Per Share (EPS)
-20.77
Revenue
-
Net Profit
-30.86M

About Genprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who cur... Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Genprex Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GNPX. The last closing price for Genprex was $2.42. Over the last year, Genprex shares have traded in a share price range of $ 2.09 to $ 42.00.

Genprex currently has 1,485,871 shares outstanding. The market capitalization of Genprex is $3.21 million. Genprex has a price to earnings ratio (PE ratio) of -0.10.

GNPX Latest News

Genprex to Present at the 2024 BIO International Convention

Genprex to Present at the 2024 BIO International Convention PR Newswire AUSTIN, Texas, May 30, 2024 Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas...

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire AUSTIN, Texas, May 14, 2024...

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors PR Newswire AUSTIN, Texas, May 13, 2024 Follows the Recent Appointment of Ryan Confer as Genprex...

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire AUSTIN, Texas, May 8, 2024 Ryan Confer Appointed Genprex President and CEO and to its Board...

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences PR Newswire AUSTIN, Texas, May. 1, 2024 AUSTIN, Texas, May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex...

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024...

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire AUSTIN, Texas, April 3, 2024...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.425-16.37764932562.5952.632.12467252.48353037CS
4-0.25-10.33057851242.424.08992.12580053.02272042CS
12-0.83-27.666666666734.08992.091103492.94092389CS
26-6.69-75.50790067728.8614.42.092783927.65914423CS
52-32.23-93.691860465134.4422.0939694618.57578126CS
156-143.03-98.5055096419145.2155.62.0984310795.73781598CS
260-53.83-96.12556308.82.091276677117.30510996CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

GNPX Discussion

View Posts
laraz5 laraz5 1 week ago
**Complete Fraud** GNPX being used to raise money from epic amounts if pure dilution and promotion?

Bogus PRs, reverse splits, rinse and repeat and some of the worst dilution even seen?

A pyramid scheme of pure theft?

Genprex?

Officers should be in jail?


Every single one of them?


IMO
👍️0
jedijazz jedijazz 1 week ago
$GNPX $2.92 -(Nasdaq) New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms :NASDAQ: GNPX - EIN Presswire https://einnews.com/article/711037589/new-company-officers-appointed-after-promising-preclinical-data-on-gene-therapy-for-anti-tumor-mechanisms-nasdaq-gnpx via
@ein_news
$NRXP
👍️ 1 💯 1 😍 1
jedijazz jedijazz 2 weeks ago
$GNPX $3.30 +6.11% ---UPDATE
President, CEO and CFO, Ryan Confer, will be providing an overview of the Company’s gene therapies for cancer and diabetes:
2024 BIO International Convention.
Date: Monday, June 3, 2024
Time: 2:00 pm PT
Venue: San Diego Convention Center -TheaterOne
👍️0
jedijazz jedijazz 2 weeks ago
$GNPX Genprex to Present at the 2024 BIO International Convention - "Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes" https://prn.to/3RdiwFv
👍️0
laraz5 laraz5 2 weeks ago
New O/S 2,098,698

It's about to get ugly?


IMO
👍️0
glenn1919 glenn1919 2 weeks ago
GNPX........................................https://stockcharts.com/h-sc/ui?s=GNPX&p=W&b=5&g=0&id=p86431144783
👍️0
jedijazz jedijazz 2 weeks ago
$GNPX Now $3.60 +48.76% Today HOD $3.96 #Bullish Exposure growing. Genprex to Present at the 2024 BIO International Convention
via PR Newswire, Thu, May 30, 2024

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes

https://www.prnewswire.com/news-releases/genprex-to-present-at-the-2024-bio-international-convention-302159043.html
👍️ 1 💪 1 😍 1
jedijazz jedijazz 2 weeks ago
$GNPX $2.72 +13.64% #Nasdaq Genprex Inc - 2024 BIO International Convention
https://finance.yahoo.com/news/genprex-present-2024-bio-international-123100674.html?soc_src=strm&soc_trk=tw via @YahooFinance
👍️0
jedijazz jedijazz 2 weeks ago
News: Genprex to Present at the 2024 BIO International Convention
PR Newswire
Thu, May 30, 2024, 8:31 AM EDT

In this article: $GNPX

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes

AUSTIN, Texas, May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.

Event: 2024 BIO International Convention
Conference Dates: June 3-6, 2024
Presentation Date: Monday, June 3, 2024
Presentation Time: 2:00 p.m. PT
Venue: San Diego Convention Center in Theater 1
Presenter: Ryan Confer, Genprex's President, Chief Executive Officer and Chief Financial Officer

Mr. Confer will deliver an overview of the Company's pioneering gene therapies for cancer and diabetes and will be available for in-person one-on-one meetings with participating attendees through the conference platform.

For those interested in meeting Genprex management during the conference, please request a meeting through the conference portal or reach out to Investor Relations at investors@genprex.com.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-the-2024-bio-international-convention-302159043.html

SOURCE Genprex, Inc.
👍️0
jedijazz jedijazz 2 weeks ago
$GNPX nice move after hours $2.37 +11.79% #Bullish #FDA
👍️ 1 💪 1 💯 1
jedijazz jedijazz 2 weeks ago
$GNPX Great article here on Genprex Inc. "Targeted Oncology related to our Acclaim-3 clinical trial in ES-SCLC that is now treating patients. Read the article here: https://ow.ly/vC3850RKIlL #lungcancer #oncology #genetherapy
👍️ 1 💪 1 💯 1
jedijazz jedijazz 3 weeks ago
$GNPX Price Target $10 -Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
US-based gene therapy company Genprex has enrolled and dosed the first subject in a Phase I/II trial to assess a combination therapy for extensive-stage small cell lung cancer (ES-SCLC).

The Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa (quaratusugene ozeplasmid) Immunogene Therapy when given in combination with Genentech’s Tecentriq.
https://finance.yahoo.com/news/genprex-dosing-subjects-trial-combination-084204787.html
👍️ 1 💪 1 😍 1
jedijazz jedijazz 3 weeks ago
$GNPX $2.2899 +3.62% Genprex Inc. #Shortsqueeze!!
👍️ 1 💪 1 💯 1 🚀 1
laraz5 laraz5 3 weeks ago
Everytime you post a price it drops?

How much Brent pay for this ridiculous promotion of loss?

Brent Suen belongs behind bars?

IMO
👍️0
jedijazz jedijazz 3 weeks ago
$GNPX $2.43 +3.40% Genprex, Inc. (Nasdaq) Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

https://www.nasdaq.com/press-release/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsar-immunogene
👍️ 1 💪 1 💯 1 😍 1
laraz5 laraz5 4 weeks ago
1,910,441 O/S GNPX refuses to update SS that's as of 3/25m


IMO
👍️0
jedijazz jedijazz 4 weeks ago
$GNPX Genprex was featured in an article by Targeted Oncology related to our Acclaim-3 clinical trial in ES-SCLC that is now treating patients. Read the article here: https://ow.ly/vC3850RKIlL #lungcancer #oncology #genetherapy
👍️ 1 💪 1 💯 1
laraz5 laraz5 4 weeks ago
Down again because GNPX is only been able to sell shares?

GNPX could be a toxic pump and dump of pure fund raising for other frauds?

GNPX will eventually dilute until the O/S is maxxed out leading to another reverse split or bankruptcy?

It's only ever gone down the Outstanding Shares only go up?

Soon the A/S can as well?

Disgraceful?


Even the promoters stink?


IMO
👍️0
jedijazz jedijazz 4 weeks ago
$GNPX Price Target $10 Maintained
The average one-year price target for
@Genprex, Inc. is $168.30. The forecasts range from a low of $10 to a high of $336. A stock’s price target is the price at which analysts consider it valued with respect to its projected earnings and historical earnings. $GNPX Price Target
The average one-year price target for @Genprex, Inc. is $168.3. The forecasts range from a low of $10.1 to a high of $336. A stock’s price target is the price at which analysts consider it valued with respect to its projected earnings and historical earnings. pic.twitter.com/3Yljr1tKbr— 🔥🔥🌐UltimateTraderX🌐🔥🔥 (@JediJazz22) May 17, 2024
👍️ 1 🚀 1
jedijazz jedijazz 4 weeks ago
$GNPX #Bullish #Nasdaq $2.61 +4.91% Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer | NASDAQ https://www.nasdaq.com/press-release/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsar-immunogene
👍️ 1 💪 1 💯 1
jedijazz jedijazz 1 month ago
$GNPX @Genprex has enrolled and dosed the first subject in a Phase I/II trial to assess a combination therapy for extensive-stage small cell lung cancer (ES-SCLC). The Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa™ https://finance.yahoo.com/news/genprex-dosing-subjects-trial-combination-084204787.html
👍️ 1 💯 1 😍 1
jedijazz jedijazz 1 month ago
$GNPX NEWS! @Genprex dosing subjects in trial of combination therapy for small-cell lung cancer


GlobalData

Wed, May 15, 2024, 4:42 AM EDT

In this article:
GNPX
+7.53%

US-based gene therapy company Genprex has enrolled and dosed the first subject in a Phase I/II trial to assess a combination therapy for extensive-stage small cell lung cancer (ES-SCLC).

The Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa (quaratusugene ozeplasmid) Immunogene Therapy when given in combination with Genentech’s Tecentriq.

The open-label dose escalation and clinical response study is enrolling patients who have not experienced tumor progression following initial treatment with Tecentriq and chemotherapy.

Its first phase aims to enroll up to 12 subjects across roughly ten clinical sites in the US to identify the maximum tolerated dose.

Should the Phase I study proceed without dose-limiting toxicities, the highest dose tested will be the recommended Phase II dose.

The Phase II portion is anticipated to involve around 50 patients at up to 15 US locations.

Treatment with Reqorsa and Tecentriq will continue until disease progression or unacceptable toxicity occurs.

Genprex plans to begin the Phase II expansion study in the second half of this year.

A futility analysis is scheduled for after the 25th participant reaches an 18-week follow-up period.

Reqorsa has received orphan drug designation and fast track status from the US Food and Drug Administration (FDA) for use in combination with Tecentriq in ES-SCLC patients whose disease has not progressed after initial standard treatment.

Genprex chief medical officer Mark Berger said: “The Phase I dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase II expansion study.

“The favourable results from our Phase I Acclaim-1 study in non-small cell lung cancer enabled us to shorten the Phase I portion of Acclaim-3.

“This should allow us to complete the Phase I portion of the study during the second half of 2024 and to advance more quickly into the Phase II expansion portion of Acclaim-3 in the second half of 2024.”

"Genprex dosing subjects in trial of combination therapy for small-cell lung cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

https://finance.yahoo.com/news/genprex-dosing-subjects-trial-combination-084204787.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
👍️0
jedijazz jedijazz 1 month ago
NEWS: $GNPX Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
PR Newswire
Tue, May 14, 2024, 8:31 AM EDT

In this article: GNPX

Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024

Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations

AUSTIN, Texas, May 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).

(PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)
(PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)
"We are excited to take this next step in our fight against lung cancers as we work to advance an innovative therapy that we believe provides hope to patients suffering with ES-SCLC, an especially aggressive form of lung cancer that has extremely limited treatment options," said Ryan Confer, President and Chief Executive Officer at Genprex. "With a median progression free survival (PFS) of 5.2 months, ES-SCLC has a particularly poor prognosis. Additionally, patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. With such limited benefit from current treatments, we believe the combination of REQORSA and Tecentriq can provide a promising new therapeutic option for the treatment of small cell lung cancer."

"The Phase 1 dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase 2 expansion study," stated Mark Berger, M.D., Chief Medical Officer of Genprex. "The favorable results from our Phase 1 Acclaim-1 study in non-small cell lung cancer (NSCLC) enabled us to shorten the Phase 1 portion of Acclaim-3. This should allow us to complete the Phase 1 portion of the study during the second half of 2024 and to advance more quickly into the Phase 2 expansion portion of Acclaim-3 in the second half of 2024. We look forward to providing study updates as we advance this potentially life-saving therapy to benefit patients battling ES-SCLC."

Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% completely lack TUSC2 protein expression. Nonclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.

About the Acclaim-3 Clinical Trial
The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC. The Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy.

The Phase 1 dose escalation portion of the Acclaim-3 clinical study is expected to enroll up to 12 patients at approximately ten U.S. clinical sites to determine the Maximum Tolerated Dose (MTD). If no dose limiting toxicities occur during the Phase 1 study, the highest dose evaluated will be the Recommended Phase 2 Dose. The Phase 2 portion of the study is expected to enroll approximately 50 patients at ten to fifteen U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024.

The primary endpoint of the Phase 2 portion of the trial is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq treatment in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.

Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for Reqorsa® Immunogene Therapy, in combination with Genentech, Inc's Tecentriq® in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov.

About Reqorsa® Immunogene Therapy
Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid-based molecules in a lipoplex form (Genprex's Oncoprex® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. In addition, REQORSA disrupts the metabolism of cancer cells by decreasing glycolysis and ATP production in cancer cells with decreased TUSC2.

Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on current therapies for patients with NSCLC, SCLC, and possibly other cancers.

Tecentriq® is a registered trademark of Genentech, Inc.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy, is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

Cision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsa-immunogene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302144415.html

SOURCE Genprex, Inc.
👍️ 1 🙂 1
ProfitScout ProfitScout 1 month ago
$GNPX News: Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors

AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner.

Prior to his appointment as Chairman, Mr. Moreno Toscano has served on Genprex's Board of Directors since March 2020. Since April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc, the US subsidiary of LFB Group, a global integrated biopharmaceutical company, and he has more than 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations and general management.

Mr. Moreno Toscano's appointment follows the recent appointment of Ryan Confer to serve as Genprex's President and Chief Executive Officer. Mr. Confer was also appointed to Genprex's Board of Directors.

Mr. Moreno Toscano commented:

"On behalf of Genprex's Board of Directors, we wish to express our support for Ryan as Genprex's new President and Chief Executive Officer. We have worked closely with Ryan over the last several years, and we have seen his robust leadership skills and exceptional operational organization. He has strengthened the company's operational and financial foundation, bolstered the company's talent and culture, added value in every company department and has continuously advanced the company's strategies year after year. I look forward to working alongside Ryan and our other fellow directors in my role as Chairman in what I believe will be a transformational time for Genprex."

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the appointment and transition of management personnel and other succession plan-related activities; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

https://c212.net/c/img/favicon.png?sn=DA12078&sd=2024-05-13 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-announces-the-appointment-of-jose-a-moreno-toscano-as-chairman-of-the-board-of-directors-302142996.html

SOURCE Genprex, Inc.
👍️ 1 💪 1 🙂 1
jedijazz jedijazz 1 month ago
$GNPX $2.36 +1.72 HOD $2.59 Genprex's Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer https://seekingalpha.com/article/4585494-genprex-gene-therapy-potential-breakthrough-diabetes-lung-cancer
👍️ 2 💪 1 💯 1
jedijazz jedijazz 1 month ago
$GNPX should be on your radar! Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Advancing novel gene therapies for patients afflicted with cancer or diabetes. Our lead drug candidate, REQORSA® Immunogene Therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, target and kill cancer cells, and stimulate the natural immune responses against cancer. https://www.genprex.com/technology/reqorsa/
👍️ 2 💯 1 😍 1
laraz5 laraz5 1 month ago
Good luck explaining your actions where you are headed Mr Varner?

IMO
👍️0
jedijazz jedijazz 1 month ago
$GNPX About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
👍️0
jedijazz jedijazz 1 month ago
$GNPX New CEO Mr. Varner co-founded Genprex in 2009, and he has served on the Company's board of directors since 2012. He has served as President and CEO of Genprex since 2016. Under Mr. Varner's leadership, Genprex became a publicly traded company in 2018 and has successfully completed two Phase 1 clinical trials, opened three additional clinical trials, expanded its intellectual property portfolio, exclusively licensed new novel gene therapy technologies and has received three U.S. Food and Drug Administration Fast Track Designations and one Orphan Drug Designation.
👍️0
jedijazz jedijazz 1 month ago
$GNPX announced Ryan Confer Appointed Genprex President and CEO and to its Board of Directors.

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of the Company's co-founder, President, Chairman and Chief Executive Officer (CEO), Rodney Varner, due to sudden complications after a courageous battle with cancer.
👍️ 1
jedijazz jedijazz 1 month ago
$GNPX News: Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner https://finance.yahoo.com/news/genprex-announces-passing-co-founder-220800772.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
👍️0
laraz5 laraz5 4 months ago
Rinse and repeat? GNPX a mechanism to steal?

The only business they might be in is dilution?

Every single person associated with GNPX should maybe be in jail?

Whos pockets did the dilution go?

IMO
👍️0
Renee Renee 4 months ago
GNPX: effective Feb. 2,2024 a one for 40 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
laraz5 laraz5 5 months ago
Still can't understand why no one from Genprex is in jail?

From the absolute beginning when they hired Redman it was destined to steal?

IMO
👍️0
wfarrance wfarrance 5 months ago
Kent
👍️0
Monksdream Monksdream 9 months ago
GNPX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
GNPX new 52 week low
👍️0
Monksdream Monksdream 10 months ago
GNPX new 52 week low
👍️0
Zorch305 Zorch305 10 months ago
.............
👍️0
laraz5 laraz5 11 months ago
The gap could be endless selling of shares raising money for anything other than research and development?

Is it theft?

Find where the money goes and shut it down?

IMO
👍️ 1
bud_fox bud_fox 11 months ago
The gap has been filled.
👍️0
SittingPretty SittingPretty 11 months ago
missed offering disclosure... sold lol
👍️0
SittingPretty SittingPretty 11 months ago
bid filled
👍️0
bud_fox bud_fox 11 months ago
Need to fill the gap @ .85. This is a pump from the Insider Financial folks. Be careful buying here, don't chase.
👍️ 1
Triple nickle Triple nickle 11 months ago
Chart play for me expect 1.20
👍️0
AJ Freely AJ Freely 11 months ago
$GNPX - Up 6.8% Pre-Market/ Current Price $0.88
Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate| 07/11/2023
👍️0
J2003 J2003 11 months ago
FDA approval!
👍️0
Gizzer211 Gizzer211 11 months ago
What kind of news would propel this stock over $1?
👍️0
laraz5 laraz5 11 months ago
No need to promote deceptive videos?

GNPX is diluting shares?

And that's it?

They have been fund raising dilution since inception and that is all they will do until bankruptcy?

These shell companies are thrown together by the same minds who have done this multiple times with other shells?

They take a shelved product, tweek it then dilute shares based off of false theories?

GNPX will go to pennies and shareholders will continue to lose?

But what happens to the hundreds of millions they steal?

Nothing ever happens?

IMO
👍️ 1
wabadon wabadon 11 months ago
$GNPX Interesting video.
https://www.genprex.com/videos/nasdaq-gnpx-is-advancing-cancer-and-diabetes-treatments/?

wabadon
👍️ 1

Your Recent History

Delayed Upgrade Clock